Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04865302
Other study ID # Kangaroo
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 1, 2021
Est. completion date December 31, 2024

Study information

Verified date November 2023
Source Medical University of Graz
Contact Nina Höller, MD
Phone 0043 316 385 30398
Email nina.hoeller@medunigraz.at
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a prospective observational pilot study investigating if skin-to-skin care (SSC) has an influence on cerebral oxygenation and perfusion measured with near-infrared spectroscopy (NIRS) compared to incubator care in ventilated preterm neonates on the first day after birth.


Description:

Background Kangaroo mother care (KMC) or skin-to-skin care (SSC) is a routine method of care in preterm neonates in neonatal intensive care units around the world. SSC is mostly defined as the skin-to-skin contact of the infant with the mother's or father's chest, which has been proven to reduce mortality, decrease severe illness, nosocomial infections and the length of hospital stay as well as to improve growth, breastfeeding and mother-child-relationship. During the last years several studies were performed showing that SSC provides comparable neonatal physiological stability compared to routine incubator care. Near-infrared spectroscopy (NIRS) enables non-invasive, continuous monitoring of oxygenation and perfusion in different tissues. Several studies have shown that SSC has no negative influence on cerebral oxygenation saturation and physiological parameters compared to routine incubator care in preterm infants with respiratory support after the 5th day after birth. Nevertheless, until now there is no information on cerebral oxygenation and physiological parameters during SSC compared to routine incubator care in preterm neonates with respiratory support during the first 24 hours after birth, when transition still takes place and may cause unstable vital signs in neonates. Cerebral hypoxia as well as hyperoxia can cause severe brain damage due to perfusion disturbances, especially in ventilated preterm neonates. Objectives Primary aim: To assess, if the burden of cerebral hypoxia (calculated as the area under the curve outside the tissue oxygenation (cStO2) target range of 55% - 76%) in preterm neonates with respiratory support is different during SSC compared to routine incubator care on the first day after birth. Secondary aims: To assess, if SSC has an influence on cFTOE (cerebral fractional tissue oxygen extraction) and routine monitoring parameters (arterial oxygen saturation [SpO2], heart rate [HR], respiratory rate [RR], mean arterial blood pressure [MABP], temperature) in preterm neonates with respiratory support compared to routine incubator care on the first day after birth. Methods Study population: Preterm neonates <37+0 weeks of gestation with respiratory support admitted to the Division of Neonatology, Department of Paediatrics and Adolescent Medicine, Medical University of Graz after vaginal delivery or caesarean section will be eligible for the study. Procedure: Patients and maternal medical history and main diagnoses, as well as routinely sampled laboratory results, provided therapy and respiratory support will be documented in each neonate.´ Measurements: For NIRS measurements the OxyPrem 1.4. (OxyPrem AG, Zurich, Switzerland) will be used. The NIRS measurements will take place once during the first day after birth before / during / after routine SSC and will last for 180 minutes. After feeding the neonates will be brought in a prone position in the incubator and the NIRS sensor will be applied on the forehead for continuous cStO2 measurements throughout the study period. The neonate will rest in this position for 60 minutes. Afterwards the neonate will be brought on the mother's or father's chest (skin to skin) in a prone position and will stay in this position for 60 minutes. Finally the neonates will be brought back into the incubator for another 60 minutes in prone position. After 180 minutes the study period is over and the NIRS sensor will be removed. Furthermore, NIRS will be combined with routine monitoring, such as pulse oxymetry (SpO2, HR), blood pressure measurements and measurements of temperature. Data will be stored in a polygraphic system (alpha-trace digitalMM, B.E.S.T. Medical Systems, Austria) for further analysis.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date December 31, 2024
Est. primary completion date October 1, 2024
Accepts healthy volunteers No
Gender All
Age group 15 Minutes to 24 Hours
Eligibility Inclusion Criteria: - Need for respiratory support (endotracheal tube [ETT], nasal continuous positive airway pressure [nCPAP], high-flow nasal cannula [HFNC]) - Decision to conduct full life support - Written informed consent Exclusion Criteria: - No decision to conduct full life support - No written informed consent - Severe congenital malformations, severe asphyxia (umbilical cord artery pH <7.00) - Cerebral malformations, posthaemorrhagic ventricular dilatation, intraventricular haemorrhage grade III, periventricular haemorrhage - Cardiovascular instability (need for catecholamines) - No need for respiratory support

Study Design


Intervention

Procedure:
SSC
Incubator phase I: After feeding the neonates will be brought in a prone position in the incubator and the NIRS sensor will be applied on the forehead for continuous cStO2 measurements throughout the study period. The neonate will rest in this position for 60 minutes. SSC phase: The neonate will be brought on the mother's or father's chest (skin to skin) in a prone position and will stay in this position for 60 minutes. Incubator phase II: The neonates will be brought back into the incubator for another 60 minutes in prone position. After 180 minutes the study period is over and the NIRS sensor will be removed.

Locations

Country Name City State
Austria Department of Pediatrics, Division of Neonatology, Medical University of Graz Graz Styria

Sponsors (1)

Lead Sponsor Collaborator
Medical University of Graz

Country where clinical trial is conducted

Austria, 

Outcome

Type Measure Description Time frame Safety issue
Other leukocyte count leukocyte count (per µl) - routinely sampled first 48 hours
Other C-reactive protein C-reactive protein (mg/l) - routinely sampled first 48 hours
Other IT-ratio IT-ratio - routinely sampled first 48 hours
Primary percent minutes of cerebral hypoxia After a 20 minutes washout period the time (percentage of minutes) of cerebral hypoxia (below 54%) will be calculated for intervention period "incubator phase I" over 40 minutes. 60 minutes
Primary percent minutes of cerebral hypoxia After a 20 minutes washout period the time (percentage of minutes) of cerebral hypoxia (below 54%) will be calculated for intervention period "SSC" over 40 minutes. 60 minutes
Primary percent minutes of cerebral hypoxia After a 20 minutes washout period the time (percentage of minutes) of cerebral hypoxia (below 54%) will be calculated for intervention period "incubator phase II" over 40 minutes. 60 minutes
Secondary Mean StO2 Mean StO2 values over 40 minutes, calculated for intervention period "incubator phase I", after washout time will be calculated 60 minutes
Secondary Mean StO2 Mean StO2 values over 40 minutes, calculated for intervention period "SSC", after washout time will be calculated 60 minutes
Secondary Mean StO2 Mean StO2 values over 40 minutes, calculated for intervention period "incubator phase II" after washout time will be calculated 60 minutes
Secondary Mean cFTOE Mean cFTOE values over 40 minutes for intervention period "incubator phase I" after washout time will be calculated 60 minutes
Secondary Mean cFTOE Mean cFTOE values over 40 minutes for intervention period "SSC" after washout time will be calculated 60 minutes
Secondary Mean cFTOE Mean cFTOE values over 40 minutes for intervention period "incubator phase II" after washout time will be calculated 60 minutes
Secondary Mean routine monitoring parameters :SpO2 SpO2 for intervention period "incubator phase I" 60 minutes
Secondary Mean routine monitoring parameters :SpO2 SpO2 for intervention period "SSC" 60 minutes
Secondary Mean routine monitoring parameters :SpO2 SpO2 for intervention period "incubator phase II" 60 minutes
Secondary Mean routine monitoring parameters: HR HR for intervention period "incubator phase I" 60 minutes
Secondary Mean routine monitoring parameters: HR HR for intervention period "SSC" 60 minutes
Secondary Mean routine monitoring parameters: HR HR for intervention period "incubator phase II" 60 minutes
Secondary Mean routine monitoring parameters: RR RR for intervention period "incubator phase I" 60 minutes
Secondary Mean routine monitoring parameters: RR RR for intervention period "SSC" 60 minutes
Secondary Mean routine monitoring parameters: RR RR for intervention period "incubator phase II" 60 minutes
Secondary Mean routine monitoring parameters: MABP MABP for intervention period "incubator phase I" 60 minutes
Secondary Mean routine monitoring parameters: MABP MABP for intervention period "SSC" 60 minutes
Secondary Mean routine monitoring parameters: MABP MABP for intervention period "incubator phase II" 60 minutes
Secondary Mean routine monitoring parameters: temperature Temperature for intervention period "incubator phase I" 60 minutes
Secondary Mean routine monitoring parameters: temperature Temperature for intervention period "SSC" 60 minutes
Secondary Mean routine monitoring parameters: temperature Temperature for intervention period "incubator phase II" 60 minutes
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Completed NCT05502510 - Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
Not yet recruiting NCT03418012 - Prevention of sPTB With Early Cervical Pessary Treatment in Women at High Risk for PTB N/A
Not yet recruiting NCT03418311 - Cervical Pessary Treatment for Prevention of s PTB in Twin Pregnancies on Children`s Long-Term Outcome N/A
Completed NCT02993744 - Maternal Inflammatory Parameters Within Routine Treatment With Betamethasone N/A
Active, not recruiting NCT02673216 - Infection and Adverse Pregnancy Outcome
Completed NCT01683565 - Preemie Tots: A Pilot Study to Understand the Effects of Prematurity in Toddlerhood Phase 4
Completed NCT01412931 - Protein and Ultrasound Indicators of Preterm Birth N/A
Completed NCT01460576 - Improving Prematurity-Related Respiratory Outcomes at Vanderbilt N/A
Completed NCT02606058 - The Australian Placental Transfusion Study (APTS): Should Very Pre Term Babies Receive a Placental Blood Transfusion at Birth Via Deferring Cord Clamping Versus Standard Cord Clamping Procedures? N/A
Terminated NCT03715530 - Use of Placental Alpha Microglobulin-1(PAMG-1) to Diagnose Premature Rupture of Membranes in Pregnant Women N/A
Completed NCT00422526 - Progesterone for Prevention of Preterm Birth in Women With Short Cervix: Randomized Controlled Trial Phase 3
Enrolling by invitation NCT04251260 - Effectiveness of Positioning in Preterm Neonates N/A
Completed NCT03668860 - India Dexamethasone and Betamethasone Phase 1
Recruiting NCT03638037 - Correlation Between Maternal Vitamin D Level And Preterm Birth
Completed NCT02225353 - Efficacy Study of a Cervical Pessary Containing Progesterone for the Prevention of Preterm Delivery Phase 2
Recruiting NCT03992534 - The FLIP-1 Study: Vaginal Lactobacillus Supplementation in Women at High Risk of Preterm Birth Phase 1
Completed NCT03144141 - Association Between EHG and Risk of Preterm Delivery in Women Hospitalized for Threatened Premature Delivery N/A
Completed NCT05210985 - Examination of the Relationship Between Home Affordances With Development
Completed NCT04811742 - Effect of Immersion Bathing and Showering Applications on Comfort Level and Physiological Parameters of Newborn N/A